

P2RX5 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP14059b**Specification**

P2RX5 Antibody (C-term) Blocking peptide - Product InformationPrimary Accession [Q93086](#)**P2RX5 Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 5026**Other Names**

P2X purinoceptor 5, P2X5, ATP receptor, Purinergic receptor, P2RX5, P2X5

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP14059b was selected from the C-term region of P2RX5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

P2RX5 Antibody (C-term) Blocking peptide - Protein Information**Name** P2RX5**Synonyms** P2X5**Function**

Receptor for ATP that acts as a ligand-gated ion channel.

Cellular Location

Membrane; Multi-pass membrane protein.

Tissue Location

Expressed at high levels in brain and immune system

P2RX5 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

P2RX5 Antibody (C-term) Blocking peptide - Images

P2RX5 Antibody (C-term) Blocking peptide - Background

The product of this gene belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel. Several characteristic motifs of ATP-gated channels are present in its primary structure, but, unlike other members of the purinoceptors family, this receptor has only a single transmembrane domain. Three transcript variants encoding distinct isoforms have been identified for this gene.

P2RX5 Antibody (C-term) Blocking peptide - References

Kotnis, S., et al. Mol. Pharmacol. 77(6):953-960(2010) Overes, I.M., et al. Cancer Immunol. Immunother. 58(3):429-439(2009) Dubyak, G.R. Mol. Pharmacol. 72(6):1402-1405(2007) Lamesch, P., et al. Genomics 89(3):307-315(2007) Duckwitz, W., et al. J. Biol. Chem. 281(51):39561-39572(2006)